好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Assessment of Hospitalizations in Patients with Generalized Myasthenia Gravis (gMG) Before and During Treatment with Ravulizumab: Results from a Global Registry
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (11:45 AM-12:45 PM)
11-016
To assess rates and characteristics of hospitalizations among patients with anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG before and during ravulizumab treatment in clinical practice (MG SPOTLIGHT Registry; NCT04202341).
Studies comparing healthcare resource utilization in patients with gMG before and after complement component 5 inhibitor therapy (C5IT) are limited.
Patients treated with ravulizumab (ravu-only subgroup) or switched from eculizumab to ravulizumab (ecu-to-ravu subgroup) with hospitalization data provided in case report forms were identified from the MG SPOTLIGHT Registry (data cutoff: 7/1/2024). Demographics and hospitalization (admission to ER, ICU, or healthcare facility) rates in the 12 months prior to and/or during ravulizumab treatment were analyzed. Primary reasons for hospitalizations were reported.
A total of 138 patients (male: 60.1%; White: 85.5%) were assessed; of these, 25/61 patients in the ravu-only subgroup and 42/77 in the ecu-to-ravu subgroup reported ≥1 hospitalization visit. For the ravu-only subgroup, the hospitalization rate decreased from 57.38/100 patient-years (PY) to 15.44/100PY during treatment. For the ecu-to-ravu subgroup, the rate decreased from 27.86/100PY during eculizumab treatment to 21.39/100PY during ravulizumab treatment. Prior to treatment, the primary reasons for visits were myasthenic crisis (ravu-only subgroup, 25.7%; ecu-to-ravu subgroup, 20.5%) or exacerbation (ravu-only subgroup, 45.7%; ecu-to-ravu subgroup, 31.3%); during treatment, most visits were for non-MG related reasons (ravu-only subgroup, 77.8%; ecu-to-ravu subgroup, 64.7%). Among patients with MG-related hospitalizations prior to ravulizumab treatment (n=50), 16 (32.0%) from the ravu-only subgroup and 24 (48.0%) from the ecu-to-ravu subgroup had ≥1 MG crisis or exacerbation. Among patients with MG-related hospitalizations during ravulizumab treatment (n=8), none reported crises or exacerbations.
These results show hospitalizations and MG crises/exacerbations among patients with gMG are reduced after ravulizumab treatment. Reductions in hospitalizations with ravulizumab were most pronounced in patients not previously treated with eculizumab, whereas the decrease in hospitalizations associated with eculizumab was maintained after switching to ravulizumab.
Authors/Disclosures
Rup Tandan, MD, FRCP, FAAN (University of Vermont (UVM)/UVM Medical Center)
PRESENTER 		Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Apellis. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Tandan has received research support from Alexion. The institution of Dr. Tandan has received research support from Apellis. The institution of Dr. Tandan has received research support from Cytokinetics.
Samir P. Macwan, MD Dr. Macwan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion,Argenx,Grifols,Kabafusion, UCB. Dr. Macwan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie,Alexion,Argenx,Grifols and UCB. The institution of Dr. Macwan has received research support from Alexion, Argenx,Immunovant, UCB.
James M. Winkley, MD Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Winkley has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Sanofi. Dr. Winkley has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Teva. Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. The institution of Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for J&J. Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for amgen . Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG therapeutics. An immediate family member of Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS. Dr. Winkley has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Teva. Dr. Winkley has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Alexion. Dr. Winkley has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for BMS. Dr. Winkley has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for amgen . Dr. Winkley has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB . Dr. Winkley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for J&J. Dr. Winkley has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for TG therapeutics. The institution of Dr. Winkley has received research support from Noveratis. The institution of Dr. Winkley has received research support from Merck. The institution of Dr. Winkley has received research support from Sanofi. The institution of Dr. Winkley has received research support from Biogen. The institution of Dr. Winkley has received research support from Alexion.
Christopher A. Scheiner, MD, PhD (TCNI) Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx Pharmaceuticals. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansssen. Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for CSL Behring . Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Scheiner has received research support from Alexion Pharmaceuticals .
Michael W. Nicolle, MD Dr. Nicolle has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Nicolle has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various legal firms.
Lida Zeinali, MD (Alexion Pharmaceuticals, Inc.) Dr. Zeinali has received personal compensation for serving as an employee of Alexion Pharmaceuticals, AstraZeneca Rare Disease. Dr. Zeinali has stock in AstraZeneca.
Chuang Liu, PhD Dr. Liu has received personal compensation for serving as an employee of Alexion.
Gary R. Cutter, PhD (University of Alabama At Birmingham) Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Ali A. Habib, MD (University of California, Irvine) Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jansen/Johnson & Johnson. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMDSerono/Merck. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jansen/Joohnson & Johnson. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Regeneron. The institution of Dr. Habib has received research support from Arcellx. The institution of Dr. Habib has received research support from Novartis. The institution of Dr. Habib has received research support from EMDSerono/Merck. The institution of Dr. Habib has received research support from Cour Pharmaceuticals.
Michael T. Pulley, MD, PhD, FAAN (University of Florida Jacksonville) Dr. Pulley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Pulley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma. Dr. Pulley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for amylyx. Dr. Pulley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Pulley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for csl/behring. Dr. Pulley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cabaletta. Dr. Pulley has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Multiple law firms.